8 minutes read
PET-MR (PET combined with MRI in a single integrated scanner) is a newer, more complex imaging modality for specific clinical applications, not a general “upgrade” to PET-CT. China’s PET-MR installations have accelerated meaningfully in recent years — from 23 units in 2020 to 51 in 2024, with the “14th Five-Year Plan” targeting 210 total [1][2]. But PET-MR is not “PET-CT plus better” — it’s meaningfully superior to PET-CT in neurological, pediatric, hepatobiliary, prostate cancer, head & neck, gynecological, cardiac, and hematological applications, while PET-CT remains the standard for most whole-body cancer staging. This article walks through China’s PET-MR availability, the clinical scenarios where PET-MR is preferred, pricing, and how to decide whether you need PET-MR or PET-CT.
What Is PET-MR and Why It Matters
PET-MR combines PET (functional/metabolic imaging) + MRI (high-contrast soft tissue imaging) in a single integrated scanner — both datasets acquired in one examination, with MR’s soft tissue contrast far exceeding CT’s.
Fundamental differences from PET-CT:
| Dimension | PET-CT | PET-MR |
|---|---|---|
| Anatomical imaging | CT (excellent for bone, lung, air contrast) | MRI (excellent for soft tissue) |
| Radiation dose | ~10–20 mSv | ~3–5 mSv (reduced by ~70%) |
| Scan duration | 20–30 minutes | 45–90 minutes (longer) |
| Soft tissue contrast | Moderate | Very high |
| Whole-body screening | Excellent | Slightly weaker (smaller field of view) |
| Neurological, hepatobiliary, prostate, and other specific scenarios | Good | Excellent |
PET-MR Availability in China (as of 2026)
Total nationwide installations: According to the 2024 Chinese Medical Association Nuclear Medicine Branch survey, mainland China had 51 PET-MR units installed — doubled from 23 just four years earlier [1]. The “14th Five-Year Plan” sets the total at 210 units with 141 new installations [2] — meaning 2026 actual installations should be in the 80–120 range.
Key regulatory change: In March 2023, the National Health Commission downgraded PET-MR from Class A to Class B large medical equipment [3] — shifting approval from “National Health Commission approval” to “Provincial Health Commission approval,” significantly lowering the configuration threshold. This is the core policy driver behind the post-2023 acceleration in Chinese PET-MR installations.
Provincial allocations: Shanghai plans 21 units, Beijing 16, Guangdong 16 [2] — these three provinces are where international patients are most likely to find PET-MR.
Major PET-MR Centers in China
The list below covers known installations; PET-MR availability changes frequently, and not every hospital that recently installed has published the information publicly. The most accurate way to confirm current availability is through the hospital IMD or a coordination service.
Beijing:
- PLA General Hospital (301) — early-installation site
- Xuanwu Hospital (GE SIGNA PET/MR) — domestic leader in neurological PET-MR; participated in the CAMIND multi-tracer PET-MR clinical trial [4]
- Peking Union Medical College Hospital — through the IMS International Medical Department
- China-Japan Friendship Hospital — comprehensive nuclear medicine capability
Shanghai:
- Fudan University Zhongshan Hospital — the city’s most comprehensive nuclear medicine system (also the global first installation site of the uEXPLORER total-body PET-CT)
- Fudan University Shanghai Cancer Center — oncology-focused PET-MR
- Shanghai Renji Hospital (Shanghai Jiao Tong University) — comprehensive imaging
- Shanghai Quanjing Medical Imaging Diagnostic Center — third-party premium imaging
- Shanghai US-China Joint Medical Imaging Center — third-party premium imaging
Guangzhou:
- Sun Yat-sen University Cancer Center (SYSUCC) — oncology-leading; PSMA PET-MR and other tracers commonly available
- Sun Yat-sen University 1st Affiliated Hospital — major Greater Bay Area international patient entry point
Shenzhen:
- The University of Hong Kong-Shenzhen Hospital (HKU-SZH) — Hong Kong-style service + standardized bilingual reporting
Hangzhou:
- Zhejiang University 2nd Affiliated Hospital International Medical Center (GE SIGNA PET/MR) — one of the most international patient-friendly PET-MR centers in the Yangtze River Delta
Chengdu:
- West China Hospital — the only confirmed PET-MR installation at a top-tier Tier-3A in southwest China
Changsha:
- Xiangya Hospital — Central China representative
Ningbo:
- Mingzhou Hospital
Main equipment models:
- Siemens Biograph mMR
- GE SIGNA PET/MR
- United Imaging uPMR 790 / uMR Jupiter PET/MR (China-domestic) — leading market share in new installations after 2020
Eight Scenarios Where PET-MR Outperforms PET-CT
Scenario 1 · Neurological disease
PET-MR has clear advantages in brain tumors, Alzheimer’s disease, and epilepsy localization — MR’s brain tissue contrast far exceeds CT, and combined with PET showing metabolic or receptor distribution, it’s the gold standard for this category.
Xuanwu Hospital’s CAMIND multi-tracer PET-MR clinical trial (NCT06092125, 2022–2028) targets exactly this area [4].
Applications:
- Brain glioma grading and biopsy targeting
- Early Alzheimer’s diagnosis (β-amyloid / Tau PET-MR)
- Difficult-to-treat epilepsy precision foci localization
- Detailed assessment of brain metastases
Scenario 2 · Pediatric oncology
PET-MR’s radiation dose of ~3–5 mSv represents a ~70% reduction compared with PET-CT [5]. For pediatric patients and adolescents requiring repeated surveillance, this radiation reduction has standalone medical value — lower long-term cumulative dose, lower long-term cancer risk.
Applications:
- Pediatric lymphoma staging and surveillance
- Pediatric bone and soft tissue tumors
- Neuroblastoma staging
Scenario 3 · Hepatobiliary and pancreatic cancers
PET-MR combines multi-parametric MR (DWI + hepatobiliary-specific contrast Gd-EOB-DTPA) + FDG / FAPI PET, with sensitivity for liver metastases, primary liver cancer, and pancreatic cancer significantly higher than PET-CT [6].
Applications:
- Hepatocellular carcinoma staging
- Detection of colorectal cancer liver metastases
- Pancreatic cancer (especially combined with FAPI tracer)
- Cholangiocarcinoma
Scenario 4 · Prostate cancer (PSMA PET-MR)
68Ga-PSMA PET-MR outperforms PET-CT for prostate local staging and neurovascular bundle involvement assessment [7] — MR’s pelvic soft tissue resolution is the key.
Applications:
- Precision local staging of prostate cancer
- Neurovascular bundle involvement assessment (determines feasibility of nerve-sparing surgery)
- Local recurrence assessment after biochemical recurrence
Scenario 5 · Head and neck cancer
For local-regional staging of oropharyngeal squamous cell carcinoma and other head and neck cancers, PET-MR outperforms PET-CT [8] — the head and neck’s complex soft tissue structures benefit from MR’s high contrast.
Applications:
- Oropharyngeal squamous cell carcinoma
- Nasopharyngeal carcinoma (especially skull base involvement assessment, combining well with SYSUCC’s nasopharyngeal cancer expertise)
- Laryngeal cancer
- Cervical lymph node assessment
Scenario 6 · Gynecological cancers
For cervical cancer, endometrial cancer, and ovarian cancer, PET-MR offers superior pelvic soft tissue contrast and is particularly valuable for:
- Local extension assessment (parametrial invasion, vaginal involvement, bladder/rectal invasion)
- Pelvic and para-aortic lymph node staging
- Treatment response evaluation
- Recurrence localization after primary treatment
PET-MR is increasingly preferred over PET-CT in many gynecologic oncology centers internationally for staging decisions that affect surgical approach.
Scenario 7 · Cardiac PET-MR
Cardiac PET-MR combines metabolic information (PET) with the cine sequences and tissue characterization (LGE, T1/T2 mapping) of cardiac MR. Particularly valuable for:
- Cardiac sarcoidosis — distinguishing active inflammation from fibrosis
- Myocarditis — assessing inflammation and necrosis
- Cardiac viability assessment — pre-revascularization planning
- Cardiac tumors — characterization and staging
Cardiac PET-MR is a specialized application; not all PET-MR centers have the cardiac expertise to interpret it well.
Scenario 8 · Multiple myeloma and bone marrow disease
PET-MR’s combination of whole-body MRI (with diffusion-weighted imaging) + FDG PET provides comprehensive bone marrow assessment that PET-CT alone cannot match. Particularly valuable for:
- Multiple myeloma staging (replacing or complementing skeletal survey)
- Treatment response assessment in multiple myeloma
- Diffuse marrow involvement evaluation
- Solitary plasmacytoma versus multiple myeloma differentiation
For multiple myeloma patients, PET-MR is increasingly considered a preferred imaging modality in international guidelines.
Pricing
PET-MR pricing is higher than PET-CT, but the gap has meaningfully narrowed in recent years:
| Type | Price Range (USD, at 6.5:1) | Notes |
|---|---|---|
| Public Tier-3A full-body PET-MR (in price-adjusted provinces: Shanghai, Guangdong, etc.) | $1,290–$1,330 (regulatory ceiling) | Within the ceiling, hospitals set their own pricing |
| Public Tier-3A full-body PET-MR (in not-yet-adjusted provinces: Beijing, Sichuan, etc.) | $1,500–$2,300 (historical range) | Typically at prior pricing standards |
| Public IMD channel | Public base + 30–60% service premium | Includes English service, expedited reporting |
| Private international hospital / third-party premium imaging center | Comparable to or slightly below public | Shanghai Quanjing, US-China Joint, etc. |
Compared with PET-CT: post-adjustment ratio is 1.3–1.4× (historically commonly 2×, now narrowed).
Compared with US: US PET-MR typically costs $3,500–$5,000+ USD; Chinese public hospitals run approximately 30–40% of US pricing.
Examination Workflow
PET-MR workflow is somewhat longer than PET-CT:
Preparation (similar to PET-CT):
- 6 hours fasting
- Blood glucose control
- Avoid vigorous exercise for 24 hours
- MR safety screening: check for metallic implants (pacemakers, prosthetic joints, aneurysm clips, etc.) — this is a hard requirement for MR examinations
Typical examination day timeline:
| Time | Activity |
|---|---|
| 8:00 arrival | Blood glucose check + MR safety screening |
| 8:15 | Inject 18F-FDG (or PSMA, FAPI, DOTATATE) |
| 8:30–9:30 | Rest quietly for 60 minutes |
| 9:30 | Enter PET-MR scanning room |
| 9:30–11:00 | Scan — 45–90 minutes (longer than PET-CT due to MR sequence time) |
| 11:00 | Examination complete |
| Total on-site time approximately 3–4 hours |
Report delivery:
- Standard outpatient: 2–3 business days
- IMD channel: can be expedited to next-day (Chinese-English bilingual)
How to Decide Between PET-MR and PET-CT?
Prefer PET-MR when:
- Brain tumors, neurodegenerative diseases, epilepsy
- Pediatric or young patients (radiation sensitivity)
- Hepatobiliary and pancreatic cancers
- Prostate cancer (especially local staging, combined with PSMA)
- Head and neck cancers
- Gynecological cancers (pelvic staging)
- Cardiac sarcoidosis, myocarditis, viability assessment
- Multiple myeloma and bone marrow disease
Prefer PET-CT when:
- Whole-body cancer staging (especially lung, breast, lymphoma where systemic evaluation is primary)
- Need to complete imaging quickly (PET-CT is ~30 minutes shorter than PET-MR)
- Contraindicated metallic implants for MR
- Cost is the priority (PET-CT is less expensive)
Both may be appropriate when:
- Initial comprehensive staging of complex or rare cancers
- High-net-worth patients prioritizing complete evaluation
- Academic research or clinical trial enrollment
Practical principle: for the majority of international patients, PET-CT is sufficient. PET-MR is “a precision tool for specific indications,” not “a comprehensive upgrade to PET-CT.”
Common Questions
Can I travel to China specifically for PET-MR? Yes. Beijing, Shanghai, Guangzhou, Hangzhou, and Chengdu all have PET-MR centers. If your condition falls into one of the eight PET-MR-preferred scenarios (neurological, pediatric, hepatobiliary, prostate, head and neck, gynecological, cardiac, bone marrow disease), choosing a PET-MR center is worth the consideration.
How does the quality of Chinese PET-MR reports compare to Western centers? Chinese major Tier-3A nuclear medicine and radiology joint reading of PET-MR matches Western top centers. Xuanwu Hospital, West China, Fudan Zhongshan, and others participate in international multicenter studies.
Can PSMA PET-MR be done? Yes — primarily at strong nuclear medicine centers in Beijing, Shanghai, and Guangzhou. Tracer availability needs to be confirmed with the hospital in advance (68Ga-PSMA has a short half-life, requiring an on-site or nearby cyclotron).
Is PET-MR safe? Are there contraindications? PET-MR’s radiation dose is meaningfully lower than PET-CT. MR contraindications: older pacemakers, aneurysm clips, implantable insulin pumps, cochlear implants, etc. — these must be disclosed to the physician in advance. Modern MR-compatible pacemakers and implants may be eligible but require specialized evaluation.
How long is the wait for PET-MR in China? Top centers may require 1–3 weeks advance scheduling — total PET-MR units remain limited and demand is high. Through the IMD channel or a coordination service, this can typically be expedited to 3–7 days.
As an international patient, can I confirm a PET-MR slot before traveling to China? Yes. MedCareInChina can confirm your PET-MR slot before you travel — avoiding the surprise of a 2-week wait upon arrival.
Bottom Line
PET-MR availability in China:
- 50+ units installed nationwide (2024 survey), growing rapidly
- Concentrated in Beijing, Shanghai, Guangzhou, Hangzhou, Chengdu
- The 2023 regulatory downgrade (Class A → Class B) has accelerated installations
Best-suited scenarios: neurological, pediatric oncology, hepatobiliary/pancreatic, prostate, head and neck, gynecological, cardiac, multiple myeloma/bone marrow — these eight categories meaningfully outperform PET-CT.
Not suited: most whole-body cancer screening — PET-CT remains sufficient.
Pricing: typically 1.3–1.4× PET-CT, in the range of $1,290–$2,300 USD (depending on hospital and province).
If you’re unsure whether PET-CT or PET-MR is more appropriate for your case, send us a brief case description. MedCareInChina will recommend based on your specific case and the optimal center’s accessibility.
→ Send your case to hello@medcareinchina.com
See Service & Refund Policy and Medical Disclaimer for service boundaries.
Sources
- Chinese Medical Association Nuclear Medicine Branch 2024 National Survey — 51 PET-MR units installed in mainland China (23 four years earlier). https://chinanm.cma.org.cn/attach/0/3be93211e1354cb78836b21cec400fb6.pdf
- “14th Five-Year Plan” Large Medical Equipment Configuration Plan — Total PET-MR target 210 units, 141 new installations. Shanghai 21, Beijing 16, Guangdong 16. Source: GSCWZFW (2023) No. 18 https://nirp.chinacdc.cn/fsaqssjb/fswsfgbzsjb/fgsjb/gfxwjsjb/202502/W020250428534267263625.pdf
- PET-MR Regulatory Downgrade 2023 — National Health Commission’s “2023 Large Medical Equipment Configuration License Management Catalog” reclassified PET-MR from Class A to Class B. https://www.gov.cn/zhengce/zhengceku/2023-03/21/content_5747678.htm
- Xuanwu Hospital CAMIND Multi-Tracer PET-MR Clinical Trial — NCT06092125, 2022–2028. https://clinicaltrials.gov/study/NCT06092125
- Pediatric PET-MR Radiation Dose Reduction — Radiation dose ~3–5 mSv, approximately 70% reduction compared with PET-CT. Source: DXY https://y.dxy.cn/hospital/6198/qjyx/article/731641/
- PET-MR Advantages for Hepatobiliary/Pancreatic Cancers — Comparison of total-body PET and PET-MR for liver metastasis diagnosis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116365/
- PSMA PET-MR Prostate Cancer Staging — 68Ga-PSMA PET-MR superior to PET-CT for prostate local staging. https://www.hanspub.org/journal/paperinformation?paperid=81883
- PET-MR Applications in Head and Neck Cancer — PET-MR superior to PET-CT for oropharyngeal squamous cell carcinoma local-regional staging. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160406/
- Provincial PET-MR Price Adjustments 2025 — Shanghai full-body ≤8,650 RMB, Guangdong ≈8,398–8,500 RMB. Sources: Sina Finance https://finance.sina.com.cn/jjxw/2025-05-16/doc-inewttpc4438743.shtml ; CLS https://www.cls.cn/detail/2037815
